Aggressive tumors and difficult choices in acromegaly

Pituitary

Volumn 17, Issue SUPPL. 1, 2014, Pages 24-29

  Carrasco, Carmen A ^a   Gadelha, Mônica ^b   Manavela, Marcos ^c   Bruno, Oscar D ^c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acromegaly; Aggressive tumors; Dopamine agonists; GH; IGF 1; Somatostatin analogs

Indexed keywords

CABERGOLINE; GROWTH HORMONE; HYDROCORTISONE; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TESTOSTERONE; THYROTROPIN; THYROXINE;

ACROMEGALY; ADD ON THERAPY; ADULT; ARTICLE; BODY GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; FACE DEFORMITY; FOLLOW UP; HUMAN; HYPERTENSION; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS ADENOMA; IMPAIRED GLUCOSE TOLERANCE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AND CENTRAL AMERICA; TRANSSPHENOIDAL SURGERY; TUMOR DIAGNOSIS;

ACROMEGALY; ADENOMA; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; MALE; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 84898791239     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0538-5     Document Type: Article

References (45)

1. Besser GM, Burman P, Daly AF (2005) Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 153(2):187-193 (Pubitemid 41167474)
2. Buchfelder M (2009) Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 12(3):256-260
3. Colao A, Grasso LF, Pivonello R, Lombardi G (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12(10): 1561-1570
4. Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol 111(1):1-7 (Pubitemid 43013820)
5. Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83(3-4):179-188
6. Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki- 67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39(5):758-766 (Pubitemid 351601606)
7. Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49(2):R69-R78
8. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M (2009) Ki-67 in pituitary neoplasms: a review - part I. Neurosurgery 65(3):429-437
9. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82-91
10. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt- DeMasters BK, Wierman ME (2012) Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 42(1): 18-28
11. Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4): 491-499
12. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58(1):86-91 (Pubitemid 36098853)
13. Minniti G, Jaffrain-Rea M-L, Esposito V, Santoro A, Tamburrano G, Cantore G (2003) Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 10(4):611-619 (Pubitemid 38094895)
14. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439-446
15. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65(6):733-744 (Pubitemid 17187407)
16. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610-617
17. Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger DW, Lioyd RV, Smyth HS, Barr A, Thorner MO, Gaylinn B, Laws ER Jr (1997) Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am J Pathol 151(3):769-784 (Pubitemid 27385609)
18. Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G, Lanzetta G, Cantore G (2004) Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumors: outcome analysis in a series of 125 patients. Neurol Sci 25(5):251-256 (Pubitemid 40069179)
19. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203-216 (Pubitemid 46554515)
20. Kim MS, Jang HD, Kim OL (2009) Surgical results of growth hormone-secreting pituitary adenoma. J Korean Neurosurg Soc 45(5):271-274
21. Dusek T, Kastelan D, Melada A, Baretic M, Skoric Polovina T, Perkovic Z, Giljevic Z, Jelcic J, Paladino J, Aganovic I, Korsic M (2011) Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience. J Endocrinol Invest 34(11):e382-e385
22. Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64(3):402-407 (Pubitemid 16035061)
23. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2):195-208 (Pubitemid 34230231)
24. Dyer EH, Civit T, Visot A, Delalande O, Derome P (1994) Transsphenoidal surgery for pituitary adenomas in children [with discussion]. Neurosurgery 34(2):207-212 (Pubitemid 24044096)
25. Abe T, Tara LA, Lüdecke DK (1999) Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 45(1):1-10 (Pubitemid 29318867)
26. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86(9):4072-4077 (Pubitemid 32848515)
27. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96(9):2732-2740
28. Espinosa de los Monteros AL, González B, Vargas G, Sosa E, Guinto G, Mercado M (2009) Surgical reintervention in acromegaly: is it still worth trying? Endocr Pract 15(5):431-437
29. Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 25(5):238-248
30. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247-271
31. Kasuki L, Colli LM, Elias PC, de Castro M, Gadelha MR (2012) Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. Arq Bras Endocrinol Metabol 56(8):501-506
32. Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM, Gadelha MR (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19(3):L25-L29
33. Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411-E1420
34. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67(2):310-315 (Pubitemid 47076313)
35. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2007) Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10(1):53-59 (Pubitemid 46562808)
36. González B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E, Mercado M (2011) Efficacy and safety of radiotherapy in acromegaly. Arch Med Res 42(1):48-52
37. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(3):454-462
38. Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K (2012) Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 67(Suppl 1):119-123
39. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
40. Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS (2011) Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14(3):276-283
41. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467-477
42. Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13(2):168-175
43. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90(10):5627-5631
44. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644-1646 (Pubitemid 40693415)
45. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160(4):529-533